2 active not recruiting, 2 completed, 2 recruiting. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 2, Completed 2, Recruiting 2 |
| Phase 1 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
Follow Lethal Congenital Contracture Syndrome 2: new trials by email Literature Review of Lethal Congenital Contracture Syndrome 2 trials Research Report on Lethal Congenital Contracture Syndrome 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) BNT326, Pumitamig - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | BioNTech SE | 880 | 2025-09-22 | 2026-10-22 |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors BNT326, Pumitamig, Itraconazole - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | BioNTech SE | 1438 | 2025-08-12 | 2026-10-09 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours HMBD-001, HMBD-001 and enzalutamide - Bladder Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Cancer Research UK | 81 | 2021-11-10 | 2025-08-11 |
| MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. Zenocutuzumab, Trastuzumab, Vinorelbine - Breast Cancer Metastatic | Phase 2 | Completed | Merus B.V. | 105 | 2018-01-15 | 2024-03-07 |
| A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) zenocutuzumab (MCLA-128) - Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion | Phase 2 | Active not recruiting | Partner Therapeutics, Inc. | 250 | 2015-01-01 | 2025-04-29 |
| A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer MM-121, Erlotinib - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Merrimack Pharmaceuticals | 162 | 2010-02-01 | 2016-08-22 |
Carcinoma, Non-Small-Cell Lung (5) · Melanoma (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Carcinoma, Hepatocellular (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Fibromatosis, Gingival, 2 (1) · Lung Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms, Castration-Resistant (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5) · Lung Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Thoracic Neoplasms (5) · Lung Neoplasms (4) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2)
zenocutuzumab (2) · Anastrozole (1) · Erlotinib Hydrochloride (1) · Fulvestrant (1) · Itraconazole (1) · Letrozole (1) · Paroxetine (1) · Trastuzumab (1) · Vinorelbine (1) · enzalutamide (1) · exemestane (1) · seribantumab (1)
BioNTech SE (2) · Cancer Research UK (1) · Merrimack Pharmaceuticals (1) · Merus B.V. (1) · Partner Therapeutics, Inc. (1)
Spain (5) · United Kingdom (5) · United States (5) · Germany (4) · Belgium (3) · Italy (3) · Australia (2) · Canada (2) · China (2) · France (2) · Netherlands (2) · South Korea (2) · Taiwan (2) · Turkey (Türkiye) (2) · Austria (1)
Alison Schram, MD (1) · Ernesto Wasserman, MD (1) · Johann de Bono, Prof (1) · Victor Moyo, MD (1)
2014 (1), 2017 (1)